Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil (KD025) in chronic graft versus host disease
NCT03640481Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Started Oct 2018; status: terminated.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03640481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03640481.